Gilead gets US FDA approval for inflammatory liver disease drug
Adds pricing in paragraph 4, company comments in paragraphs 6-7, details on common symptom in paragraphs 10-12
By Puyaan Singh and Leroy Leo
Aug 14 (Reuters) -The U.S. Food and Drug Administration on Wednesday approved Gilead Sciences' GILD.O liver disease treatment, Livdelzi, which it gained through a $4.3 billion buyout of CymaBay Therapeutics earlier this year.
The disease, primary biliary cholangitis (PBC), causes inflammation of the small bile ducts in the liver and can eventually destroy them. It mainly affects women aged 35 to 60.
The American Liver Foundation estimates that about 65 out of every 100,000 women in the U.S. have PBC.
Livdelzi's list price is $12,606 per 30 days of therapy. Rival drug, Iqirvo, from Ipsen IPN.PA costs $11,500 per month.
BMO Capital Markets analyst Evan Seigerman sees $847 million in annual peak sales for Livdelzi, accelerating growth for Gilead's liver drug portfolio, which posted a 17% increase in second-quarter revenue.
Gilead expects the drug to have modest sales in the first couple of quarters, before sales become "much more meaningful in 2025 and beyond", Chief Commercial Officer Johanna Mercier told Reuters.
Mercier said the drug was a "great strategic fit", given the company's experience with liver disease treatments.
The FDA's accelerated approval for Livdelzi is based on a 193-patient study, in which 62% of the participants who received a combination of the drug and ursodeoxycholic acid (UDCA) showed an improvement in biochemical response after one year.
About 40% of PBC patients do not respond to the generic drug UDCA as their first line of treatment, according to a study last year.
Gilead's once-daily pill also showed a statistically significant reduction in itching — a symptom that more than half of the PBC patients experience.
Treatment with Ipsen's Iqirvo has also not shown statistically significant reduction in itching, whereas Intercept Pharmaceuticals' ICPT.MX Ocaliva can worsen itching.
The FDA's accelerated nod to Livdelzi can be converted to a standard approval if it shows improvement in survival or preventing liver function deterioration in a confirmatory study.
Reporting by Puyaan Singh, Christy Santhosh and Leroy Leo in Bengaluru; Editing by Devika Syamnath and Shilpi Majumdar
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
